Skip to main content
Erschienen in: Rheumatology International 1/2011

01.01.2011 | Original Article

Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis

verfasst von: Minyoung Her, YounJae Lee, EunUk Jung, TaeHee Kim, Dongyook Kim

Erschienen in: Rheumatology International | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Although subclinical liver disease is common in systemic lupus erythematosus (SLE), strikingly high levels of liver enzymes are rare. Our aim was to determine the cause of high levels of liver enzymes in lupus patients, particularly in patients diagnosed with toxic hepatitis. We performed a retrospective chart review of SLE patients treated at the Inje University Hospital between 2001 and 2008. We defined liver enzyme abnormality as a twofold or greater increase in two or more of the following four components: total bilirubin, AST, ALT and LDH or ALP. Acute toxic hepatitis was diagnosed by a score ≥5 in the Roussel Uclaf Causality Assessment Method. Of 141 SLE patients 46 (32.6%) met strict criteria for the liver enzyme abnormality. In total, 11 patients (7.8%) in this study had presumed toxic hepatitis associated with either herbal medicines (n = 6), anti-tuberculosis medications (n = 3), antibiotics (n = 1) or valproic acid (n = 1). There were striking laboratory abnormalities in the groups diagnosed with toxic hepatitis (mean peak values: AST 775 ± 464 U/L, ALT 400 ± 447 U/L, ALP 767 ± 408 U/L, LDH 1,469 ± 779 U/L). All six patients with herbal-induced toxic hepatitis were in the active SLE state. After cessation of the suspected causative medication and subsequent administration of steroids, liver enzyme levels were improved. Herbal medicines and anti-tuberculosis medications, known to cause toxic hepatitis, can also induce increased liver enzyme levels in lupus patients. However, since most herbal medicines contain a mixture of various products, we could not ascertain what specific ingredient induced the increase in liver enzyme levels.
Literatur
1.
Zurück zum Zitat Hallegua DS, Wallace DJ (2002) Gastrointestinal manifestation and hepatic manifestation. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott William & Wilkins, Philadelphia, pp 843–861 Hallegua DS, Wallace DJ (2002) Gastrointestinal manifestation and hepatic manifestation. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott William & Wilkins, Philadelphia, pp 843–861
2.
Zurück zum Zitat Pittler MH, Ernst E (2003) Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18:451–471CrossRefPubMed Pittler MH, Ernst E (2003) Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther 18:451–471CrossRefPubMed
3.
4.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
5.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640CrossRefPubMed
6.
Zurück zum Zitat Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs—i. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323–1330CrossRefPubMed Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs—i. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46:1323–1330CrossRefPubMed
7.
Zurück zum Zitat Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs—ii. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46:1331–1336CrossRefPubMed Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs—ii. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46:1331–1336CrossRefPubMed
8.
Zurück zum Zitat Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497CrossRefPubMed Czaja AJ, Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36:479–497CrossRefPubMed
9.
Zurück zum Zitat Gibson T, Myers AR (1981) Subclinical liver disease in systemic lupus erythematosus. J Rheumatol 8:752–759PubMed Gibson T, Myers AR (1981) Subclinical liver disease in systemic lupus erythematosus. J Rheumatol 8:752–759PubMed
10.
Zurück zum Zitat Runyon BA, La Brecque DR, Anuras S (1980) The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 69:187–194CrossRefPubMed Runyon BA, La Brecque DR, Anuras S (1980) The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 69:187–194CrossRefPubMed
11.
Zurück zum Zitat Kang SH, Kim JI, Jeong KH, Ko KH, Ko PG, Hwang S et al (2008) Clinical characteristics of 159 cases of acute toxic hepatitis. Korean J Hepatol 14:483–492CrossRefPubMed Kang SH, Kim JI, Jeong KH, Ko KH, Ko PG, Hwang S et al (2008) Clinical characteristics of 159 cases of acute toxic hepatitis. Korean J Hepatol 14:483–492CrossRefPubMed
12.
Zurück zum Zitat Miller MH, Urowitz MB, Gladman DD, Blendis LM (1984) The liver in systemic lupus erythematosus. Q J Med 53:401–409PubMed Miller MH, Urowitz MB, Gladman DD, Blendis LM (1984) The liver in systemic lupus erythematosus. Q J Med 53:401–409PubMed
13.
Zurück zum Zitat Lai NS, Lin RH, Lai RS, Kun UC, Leu SC (2001) Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice with an ancient Chinese herb, Ganoderma tsugae. Lupus 10:461–465CrossRefPubMed Lai NS, Lin RH, Lai RS, Kun UC, Leu SC (2001) Prevention of autoantibody formation and prolonged survival in New Zealand Black/New Zealand White F1 mice with an ancient Chinese herb, Ganoderma tsugae. Lupus 10:461–465CrossRefPubMed
15.
Zurück zum Zitat Seeff LB (2007) Herbal hepatotoxicity. Clin Liver Dis 11:577–596, vii Seeff LB (2007) Herbal hepatotoxicity. Clin Liver Dis 11:577–596, vii
16.
Zurück zum Zitat Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega M et al (2007) Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 13:329–340PubMed Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega M et al (2007) Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol 13:329–340PubMed
17.
Zurück zum Zitat Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C (1997) Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 92:703–704PubMed Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C (1997) Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 92:703–704PubMed
19.
Zurück zum Zitat Chitturi S, Farrell GC (2000) Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 15:1093–1099CrossRefPubMed Chitturi S, Farrell GC (2000) Herbal hepatotoxicity: an expanding but poorly defined problem. J Gastroenterol Hepatol 15:1093–1099CrossRefPubMed
Metadaten
Titel
Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis
verfasst von
Minyoung Her
YounJae Lee
EunUk Jung
TaeHee Kim
Dongyook Kim
Publikationsdatum
01.01.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 1/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1237-4

Weitere Artikel der Ausgabe 1/2011

Rheumatology International 1/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.